In the News

CNBC: Experts seriously doubt whether patent waivers on Covid-19 vaccines will ever come to be

By January 22, 2022January 25th, 2022No Comments

From CNBC:

It’s been well over a year since a landmark proposal brought the issue of patent waiver for the mRNA Covid vaccine to the spotlight. But many observers don’t see that waiving the intellectual property (IP) rights on Covid vaccines is an effective way to put a stop to the pandemic.

Supporters of patent waivers like Harsha Thirumurthy, associate professor of medical ethics and health policy at the University of Pennsylvania, argue the issue lies at the heart of the reason why vaccines are less accessible in lower-income countries.

“It limits how much manufacturing there can be of that product or that vaccine,” said Thirumurthy, adding it keeps the price “artificially high enough that it limits the ability of other countries in the world.

Read the full story in CNBC. 

News Mention

Topics